Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Juan Pablo FriasJill MaaskeLisa SuchowerLars JohanssonPaul D HockingsNayyar IqbalJohn P H WildingPublished in: Diabetes, obesity & metabolism (2021)
Overall, glycaemic control, metabolic benefits and efficacy were better maintained with DAPA+SAXA+MET than with GLIM+MET in T2D.